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Abstract
Dendritic cell (DC)-mediated presentation of MHC class I (MHC-I)/peptide complexes is a crucial first step in the priming of
CTL responses, and the cytoplasmic tail of MHC-I plays an important role in modulating this process. Several species express
a splice variant of the MHC-I tail that deletes exon 7-encoding amino acids (D7), including a conserved serine
phosphorylation site. Previously, it has been shown that D7 MHC-I molecules demonstrate extended DC surface half-lives,
and that mice expressing D7-K
b generate significantly augmented CTL responses to viral challenge. Herein, we show that
D7-D
b-expressing DCs stimulated significantly more proliferation and much higher cytokine secretion by melanoma
antigen-specific (Pmel-1) T cells. Moreover, in combination with adoptive Pmel-1 T-cell transfer, D7-D
b DCs were superior to
WT-D
b DCs at stimulating anti-tumor responses against established B16 melanoma tumors, significantly extending mouse
survival. Human DCs engineered to express D7-HLA-A*0201 showed similarly enhanced CTL stimulatory capacity. Further
studies demonstrated impaired lateral membrane movement and clustering of human D7-MHC-I/peptide complexes,
resulting in significantly increased bioavailability of MHC-I/peptide complexes for specific CD8
+ T cells. Collectively, these
data suggest that targeting exon 7-encoded MHC-I cytoplasmic determinants in DC vaccines has the potential to increase
CD8
+ T-cell stimulatory capacity and substantially improve their clinical efficacy.
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Introduction
Presentation of MHC class I (MHC-I)/peptide complexes on
the cell surface of antigen presenting cells (APC) is crucial first step
in the activation of cytotoxic T lymphocyte (CTL)-mediated anti-
viral and anti-tumor immune responses [1]. Amongst APCs,
activated DCs are by far the most potent for initiating CD8
+ T-cell
responses; thus, they have held great promise for use in vaccines
aimed at eliciting or boosting pathogen- or tumor antigen-specific
CTLs [2,3]. Many studies have reported strong induction of CTL
responses following DC-based vaccination in both animal models
and in selected clinical trials involving cancer patients and those
harboring chronic viral infections [4–8]. However, although the
majority of experimental DC vaccines have been successful at
generating antigen-specific CTLs, clinical responses have re-
mained sporadic, underscoring a need to improve the efficacy of
DC-based vaccination [9–11].
A number of studies have demonstrated that the ,35 amino
acid cytoplasmic tail of MHC-I plays a critical role in intracellular
trafficking, DC-mediated antigen presentation and CTL priming
[12–15]. Encoded by two separate exons (6 and 7) and containing
a number of highly conserved features, it has been shown that
deletion of the entire MHC-I cytoplasmic tail results in a complete
abrogation of anti-viral CTL responses in vivo [13]. Subsequently,
it was shown that a membrane-proximal tyrosine residue (Tyr-320)
encoded by exon 6 forms part of a putative endocytic motif which
is required for proper MHC-I trafficking through DC endosomal
compartments, cross-presentation of exogenous antigens, and anti-
viral CTL priming [14,15]. By contrast, deletion of thirteen exon
7-encoded cytoplasmic amino acids led to a significant enhance-
ment of anti-viral CTL responses in vivo [14]. This is of particular
interest because exon 7-deleted MHC-I (D7) is a natural splice
variant expressed by a number of diverse species, and this isoform
lacks at least one conserved serine phosphorylation site, Ser-335
[16–20]. Exon 7-deleted MHC-I molecules have been shown to
exhibit delayed internalization in a number of cell types, including
DCs [12,15,21]. However, unlike Tyr-320-mutated MHC-I, D7
molecules retain their ability to recycle through DC endosomal
compartments, and appear to be fully functional at acquiring and
presenting both endogenous and exogenous antigens [15,22].
In DCs, wild-type (WT) surface MHC-I molecules are rapidly
and constitutively internalized and recycled through endocytic
compartments [15,23–25]. This cytoplasmic tail-dependent pro-
cess limits the surface half-life of MHC-I/peptide complexes and,
of critical importance for antigen-loaded DC-based vaccines, likely
places severe constraints on the availability of these ligands for
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22939Figure 1. DC-mediated antigen presentation by exon 7-deleted H-2D
b significantly augments CD8
+ T-cell effector function. (A) Bone
marrow-derived DCs were transduced to express either wild-type (WT) H-2D
b/GFP, exon 7-deleted (D7) H-2D
b/GFP, or GFP alone at comparable
levels, as determined by flow cytometry. (Bt oD ) Transduced DCs were pulsed with the indicated concentrations of hgp100(25–33) peptide, washed,
and co-cultured with gp100-specific Pmel-1 effector CD8
+ T cells, followed by (B) flow cytometric analysis after 4 h to determine intracellular IFN-c
production and (C) CD107a expression. (D) IFN-c in 18 h co-culture supernatants, as determined by ELISA. (E) Cytokine release by naı ¨ve Pmel-1 T cells
stimulated with transduced, hgp100 peptide-pulsed (10 nM) DCs, as determined by Luminex after 72 h co-culture. All results are representative of a
minimum of 4 replicate experiments. U, untransduced DCs.
doi:10.1371/journal.pone.0022939.g001
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+ T cells. We reasoned that expression
of the D7 MHC-I isoform, with its combined attributes of
impaired cell surface internalization plus intact cross-presentation
capacity, might facilitate superior antigen presentation and
therefore more efficient CTL activation. To test this hypothesis,
we compared the relative capacity of WT and D7 MHC-I
molecules to stimulate antigen-specific CTL responses in the
context a DC-based vaccine. We report here that exon 7-deleted
MHC-I molecules stimulated superior viral-specific and tumor-
specific CTL responses in both murine and human systems, and
provided a significant therapeutic advantage in a tumor treatment
model of B16 melanoma. Collectively, these results provide a
general strategy for augmenting MHC-I-mediated antigen pre-
sentation, and suggest that direct targeting of exon 7-encoded
cytoplasmic determinants in human DC vaccines may substan-
tially improve their capacity to stimulate CTL-mediated immu-
nity.
Results
In order to directly assess the CD8
+ T-cell stimulatory capacity
of exon 7-deleted MHC-I, we utilized lentiviral vector-mediated
gene delivery to express comparable amounts of WT H-2D
b or D7
H-2D
b in bone marrow-derived DCs derived from DBA/2 mice
(haplotype H-2
d). Green fluorescent protein (GFP) was also
expressed from a downstream internal ribosome entry site (IRES),
and an empty-IRES-GFP vector was used as a negative control
(Fig. S1A). DC transduction efficiencies typically ranged from ,15
to 30%, as assessed by flow cytometry (Fig. 1A). Transduced DCs
were pulsed with titrated amounts of a D
b-restricted melanoma
tumor-associated antigen hgp100, and used to stimulate gp100-
specific Pmel-1 CD8
+ effector T- cells in vitro. After 4 h of co-
culture, T cells were assessed by flow cytometry for both surface
expression of CD107a (a marker of degranulation) and intracel-
lular IFN-c. As shown in Fig. 1B, D7-D
b transduced DCs
stimulated a much higher percentage of Pmel-1 T-cells compared
to DCs expressing WT-D
b (71% vs. 20%). Similar results were
observed for stimulation of degranulation and cytokine production
across a range of peptide concentrations (Figs. 1C and 1D).
Notably, D7-D
b-expressing DCs were capable of inducing IFN-c
production at peptide concentrations at least 10-fold lower than
the lower limit of cytokine detection for DCs expressing WT-D
b
(Fig. 1D). Moreover, in the context of an in vitro priming assay, D7-
D
b DCs elicited markedly higher levels of inflammatory cytokines
IFN-c, IL-2, TNF-a, and GM-CSF from stimulated naı ¨ve Pmel-1
T-cells (Fig. 1E).
We next assessed whether D7-D
b DCs could also stimulate
enhanced naı ¨ve CD8
+ T-cell proliferation. Naı ¨ve Pmel-1 T cells
were labeled with CFSE and co-cultured for 4 days with either
WT-D
b or D7-D
b-expressing DCs pulsed with titrated doses of
hgp100. As shown in Fig. 2A, DCs expressing D7-D
b stimulated
significantly higher levels of Pmel-1 T-cell proliferation under all
conditions tested. The most striking differences were observed at
the lowest peptide concentrations: WT-D
b-expressing DCs pulsed
with 0.1 nM hgp100 peptide stimulated negligible Pmel-1 T-cell
proliferation by day 4, whereas D7-D
b DCs pulsed with the same
dose of antigen stimulated robust proliferation (Fig. S1B). In order
to compare DC vaccine-induced T-cell proliferation in vivo,
peptide-pulsed DCs and naı ¨ve Pmel-1 T cells were co-injected
i.v. into C57BL/6 recipient mice. Following injection, peripheral
blood was analyzed at different time points to quantitate Pmel-1 T
cells. Similar to the in vitro results, mice injected with D7-D
b DCs
had peripheral blood Pmel-1 T-cell percentages at day 6 that were
,4-fold higher than mice injected with WT-D
b DCs (16% vs. 4%,
Fig. S1C).
We next investigated whether D7 MHC-I-expressing DCs could
induce better antigen-specific anti-tumor responses in vivo using a
well-established adoptive Pmel-1 T-cell transfer model to treat
gp100-expressing B16 melanoma tumors [6,26]. Under this
treatment protocol, mice with 7-day subcutaneous B16 tumors
were treated by i.v. co-administration of Pmel-1 T cells and
hgp100 peptide-pulsed DCs. As shown in Fig. 2B, mice treated
with a D7-D
b DC vaccine demonstrated significantly delayed
tumor growth compared to mice administered a WT-D
b DC
vaccine (p=0.04 at day 23). This also correlated well with the
percentage of Pmel-1 T cells in the blood of tumor-bearing
animals, which was higher in the D7-D
b DC group at days 7 and
21 following adoptive transfer (Fig. 2C). Importantly, mice treated
with D7-D
b DCs showed a significant survival benefit compared to
mice treated with WT-D
b DCs, surviving an average of 50%
longer following treatment (mean survival 31 d vs. 20 d,
p=0.0004, Fig. 2D). Collectively, these results demonstrated that
D7 MHC-I could provide a substantial advantage over WT MHC-
I for stimulating anti-tumor CTL responses in a DC-based cancer
vaccine setting.
The results from the murine studies prompted us to next assess
whether the D7 isoform of HLA class I could similarly boost
human CTL responses. Thus, we designed lentiviral vectors to
express both D7 and WT isoforms of HLA-A*0201, and used
them to transduce both CD34
+-derived DCs and the human KG-
1 DC-like cell line [27] to express comparable surface levels of
HLA-A*0201 (Figs. S2A and B). Transduced DCs were then
pulsed with the HLA-A*0201-restricted melanoma tumor-associ-
ated antigen MART-1 and used to stimulate MART-1-specific
CD8
+ tumor-infiltrating lymphocytes (TIL). Similar to the murine
studies, D7-A2 DCs were superior to WT-A2 DCs at eliciting
MART-1-specific IFN-c production from TIL, whether expressed
by KG-1 cells or transduced primary CD34
+ DCs (Fig. 3A). We
also compared the relative abilities of peptide-pulsed DCs to
stimulate influenza matrix protein 1 (Flu M1)-specific CD8
+ T
cells derived from the peripheral blood mononuclear cells (PBMC)
of normal donors. As shown in Fig. 3B, KG-1 cells expressing D7-
A2 elicited significantly greater Flu M1-specific inflammatory
cytokine/chemokine production compared to WT-A2 KG-1 cells,
with IFN-c, MIP-1a, and MIP-1b secretion being 3- to 5-fold
higher. In addition, IL-2, MCP-1, and TNF-a levels were typically
.10-fold higher than WT-A2 stimulated T-cell cultures, which
often had barely detectable levels of these cytokines. As observed
Figure 2. Exon 7-deleted H-2D
b induces enhanced CD8
+ T-cell proliferation and improved anti-tumor responses. (A) WT-H-2D
b/GFP-,
D7-H-2D
b/GFP-, or GFP-tranduced DCs were pulsed with titrated concentrations of hgp100 (25–33) peptide, washed, and used to stimulate CFSE-
labeled, naı ¨ve Pmel-1 CD8
+ T cells. Flow cytometric analysis of gated Pmel-1 cells indicates extent of T-cell proliferation at d2, d3, and d4 of co-culture,
as measured by CFSE dilution. Numbers on histograms represent the percentage of divided T cells following stimulation with DCs expressing WT-
H2D
b (blue) or D7-H2D
b (black). (Bt oD ) Mice bearing established, subcutaneous B16 tumors were treated by co-adoptive transfer of Pmel-1 CD8
+ T
cells and transduced DCs pulsed with hgp100 peptide (300 nM), followed by 3 days of IL-2. (B) B16 tumor growth, as monitored following adoptive
transfer. (C) Relative percentages of Pmel-1 T-cells in the peripheral blood of treated animals, as determined by flow cytometry at d7 and d21 post-
treatment. (D) Kaplan-Meier survival analysis of treated mice. N=8 mice per group. All data are representative of a minimum of 3 replicate
experiments.
doi:10.1371/journal.pone.0022939.g002
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specific IFN-c secretion at peptide doses .10-fold lower than the
minimal threshold observed for WT-A2 KG-1 cells (Fig. 3C).
Transduced human DCs were also assessed for their capacity to
stimulate the in vitro expansion of HLA-A*0201-restricted CD8
+ T-
cells from normal donor PBMC. As shown in Fig. 3D, Flu M1
peptide-pulsed D7-A2 DCs consistently induced superior expan-
sion of Flu M1-specific T-cells compared with DCs expressing
WT-A2, an effect that was most pronounced at limiting peptide
concentrations. Similar results were also observed for the
expansion of CMV pp65-specific T cells from PBMC following
a single round of in vitro stimulation with transduced DCs (Fig. 3E).
Despite their distinct proliferation indices, CD8
+ T cells expanded
by either D7-A2 or WT-A2-expressing DCs were found to be
indistinguishable with regard to functional avidity, IFN-c
secretion, and degranulation capacity (Fig. S2C). DC-induced in
vitro expansion of low-frequency, melanocyte/melanoma antigen
MART-1 and gp100-specific CD8
+ T cells from HLA-A2-positive
donors was also attempted, but was found to be considerably less
robust compared with antiviral T-cell expansion, particularly
within the context of a single round of DC stimulation. For these
self/tumor antigens, we did not see a statistical difference between
DCs expressing D7-A2 and DCs expressing WT-A2 at inducing
CD8
+ T-cell expansion from donor PBMC (Fig. S2D).
To gain insights into the mechanisms by which the D7 MHC-I
splice variant augments CD8
+ T-cell stimulation, we first utilized a
TCR-like mAb that recognizes MART-1/HLA-A*0201 peptide
complexes in order to measure surface complex stability over time.
Consistent with murine studies [15], D7-A2/MART-1 peptide
complexes demonstrated extended cell surface half-lives that were
approximately twice that of WT-A2/peptide complexes in KG-1
cells (,16 h vs. ,8 h, Fig. 4A). Confocal microscopy of
transduced KG-1 cells at 4uC revealed similar steady-state plasma
membrane distributions of WT and D7 HLA-A*0201. However,
when the incubation was performed at 37uC, D7-A2 molecules
demonstrated substantially impaired lateral membrane movement
and polar ‘capping’ compared with WT-A2, instead remaining
relatively evenly dispersed at the plasma membrane (Figs. 4B and
4C). Furthermore, MART-1-specific CD8
+ T cells (red) co-
cultured with peptide-pulsed KG-1 cells expressing WT-A2-GFP
fusion proteins induced very similar clustering of WT-A2-GFP
molecules that was invariably localized at the region of the DC
membrane in direct contact with the T-cell (Fig. 4D). However, for
D7-A2-GFP molecules, little or no such membrane clustering was
observed in response to CD8
+ T-cell contact (Fig. 4D). As
expected, the increased spatial distribution of membrane D7-A2/
peptide complexes was also associated with an increase in the
mean number of MART-1-specific T cells capable of forming
conjugates with co-cultured D7-A2 KG-1 cells on a per-APC basis
after 2 h of co-culture (Fig. 4E). These results are consistent with
those obtained in murine systems (Fig. 1B and [14]). At later time
points of co-culture (.6 h), larger order clusters of DC-T cell
conjugates formed, typically containing 50 to 300 cells each, which
were dependent on the presence of MART-1 peptide (Fig. 4F).
APC-T cell clusters containing D7-A2-expressing DCs were
significantly larger and more numerous than those containing
WT-A2 DCs, a difference that was most striking at limiting doses
of peptide (Fig. S2E).
Discussion
These results provide proof of principle that human DC-
mediated antigen presentation and subsequent CTL priming
responses can be modulated by altering specific elements of the
MHC-I cytoplasmic tail. Exon 6-encoded determinants (Tyr-320
in particular) have been shown to be crucial for DC-mediated
CTL priming [14], and therefore can be considered a domain that
positively regulates CTL responses. Exon 7-encoding determi-
nants, by contrast, appear to negatively regulate CTL responses, as
evidenced by the superior CD8
+ T-cell stimulation capacity of D7
MHC-I molecules. Sequence analysis of .10,000 human
expressed sequence tags (ESTs, http://www.ncbi.nlm.nih.gov/
dbEST/) for HLA-A, -B, and –C suggests that exon 7-deleted
splice variants of MHC-I do not exist in humans. Although D7-
MHC-I isoforms have been reported to occur in mice, cows, and
chickens, they have not been reported to occur naturally in any
primates, perhaps implying that exon 7 splicing may have been
lost during evolution. Nonetheless, a D7 isoform of HLA-A*0201
showed a significantly enhanced capacity to stimulate human
CD8
+ T cells, suggesting that a potential loss of exon 7 splicing in
humans during evolution may have had functional implications for
adaptive immunity, potentially providing protection from CTL-
mediated autoimmunity or excessive inflammatory responses.
Collectively, our data in both murine and human systems
demonstrate that D7 MHC-I provides significant advantages over
WT molecules for inducing superior CTL responses. Although
reduced MHC-I DC surface internalization contributed to this
effect, much of the increased stimulatory capacity by D7 was
observed at early time points of DC-T cell contact (1 to 3 hours),
when WT MHC-I molecules had yet to undergo significant
internalization. Confocal microscopy studies revealed that CD8
+
T-cell recognition of cognate antigen on peptide-pulsed APCs
induced rapid clustering or ‘capping’ of WT MHC-I molecules at
the site of T-cell contact that greatly limited the bio-availability of
MHC-I/peptide complexes for CD8
+ T cells. By contrast, exon 7-
deleted MHC-I molecules showed greatly impaired T-cell induced
clustering, resulting in increased MHC-I/peptide complex bio-
availability and enabling APCs to stimulate more CD8+ T cells on
a per-cell basis. As predicted, DCs engineered to express D7
MHC-I augmented T-cell mediated anti-tumor immunity and
significantly extended mouse survival, suggesting that similar
strategies could improve efficacy of human DC vaccines designed
to elicit viral or tumor antigen-specific CTL responses. However,
looking beyond the engineered expression of specific D7 HLA
alleles in DCs, it may be more effective to target exon 7-encoded
determinants pharmacologically in order to neutralize their
negative impact on CTL priming, an approach that could
Figure 3. Exon 7-deleted HLA-A*0201 augments human CD8
+ T-cell inflammatory cytokine secretion and in vitro proliferation.
Human KG-1 cells and primary CD34
+ DCs were transduced to express either wild-type HLA-A*0201 (WT-A2) or D7-HLA-A*0201 (D7-A2). (A)
Transduced DCs were pulsed with MART-1 peptide (100 nM), washed, and co-cultured with MART-1-specific CD8
+ T cells. Antigen-specific IFN-c
secretion was then determined by ELISA of overnight culture supernatants. (Bt oD ) Transduced KG-1 cells were pulsed with FluM1 peptide (100 nM),
and used to stimulate influenza-specific CD8
+ T cells isolated from normal donors. (B) Specific inflammatory cytokine release in response to DC
stimulation for 18 h, as determined by Luminex. (C) Specific IFN-c secretion in response to titrated amounts of FluM1 peptide. (D) In vitro expansion
of FluM1-specific CD8
+ T cells following 8d stimulation with FluM1-pulsed KG-1 cells, as determined by tetramer analysis. (E) Comparison of the total
number of FluM1 and CMVpp65-specific CD8
+ T cells following a single in vitro stimulation with peptide-pulsed WT-A2 or D7-A2-expressing KG-1
cells. All data are representative of at least 4 replicate experiments.
doi:10.1371/journal.pone.0022939.g003
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for CD8
+ T cells. (A) KG-1 cells transduced to express either WT- or D7-HLA-A*0201 were pulsed with MART-1 peptide (20 mM), washed, then
stained with a TCR-like mAb specific for HLA-A2/MART-1 complexes at different time points following cell culture at 37uC. Graph depicts the mean
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expressed HLA-A, -B, and -C alleles.
Many of the cellular mechanisms that govern MHC-I/peptide
complex clustering, internalization and turnover in DCs remain to
be elucidated. However, exon 7 does encode a highly conserved
serine phosphorylation site, Ser-335, that may serve to link MHC-
I trafficking and antigen presentation with as-yet unidentified
cellular kinases and phosphatases [18,28]. In addition, exon 6
contains at least two other potential sites for post-translational
modifications: a putative phosphorylation site at Tyr-320 [29], and
a highly-conserved ubiquitination site at Lys-316 [30]. If these
modifications modulate MHC-I function in vivo as might be
expected, inhibitors of the kinases, phosphatases, or ubiquitin
ligases that utilize the MHC-I tail as a substrate could be highly
immunomodulatory. Lastly, it will be of interest to determine the
nature of cytoskeletal components and trafficking machinery in
DCs that bind to or associate with the MHC-I tail, potentially in
response to one or more of these modifications. These studies open
a door toward the exciting possibility of direct pharmacological
manipulation of CTL priming responses at the level of antigen
presentation, through direct targeting of the MHC-I cytoplasmic
tail.
Materials and Methods
Dendritic cell transductions
Bone marrow-derived murine DCs were transduced on culture
day 3 with lentiviral vectors encoding WT-D
b-IRES-GFP, D7-D
b-
IRES-GFP, or empty-IRES-GFP at a multiplicity of infection
(MOI) of 5 in RPMI, with GM-CSF (50 ng/ml), and polybrene
(4 mg/ml) by spinfection, as described (see Methods S1). Transduced
cells were then cultured for 7 additional days, supplemented with
GM-CSF. Cells were collected and analyzed by FacScan (BD
Biosciences) for viability and expression of GFP and H-2D
b before
use. Human HLA-A*0201 negative KG-1 cells [27] or CD34-
derived DCs were transduced with lentiviral vectors encoding
either WT-HLA-A*0201 or D7-HLA-A*0201 in XVivo-15 serum
free media (Cambrex) at MOI 5 in polybrene. Cells were then
expanded in the appropriate cell media and cultured for 5 days
before use. KG-1 cells expressing similar cell surface levels of WT-
A2 and D7-A2 were isolated by cell sorting. Transduced primary
DCs were normalized to ensure that the same number and
percentage of WT- and D7-MHC-I expressing cells were used for
all functional experiments.
T-cell assays
Cytokine secretion. Transduced murine DCs were pulsed
with titrated concentrations of hgp100(25–33) peptide, which is a
human analog of the mouse gp100(25–33) epitope that is restricted
to H-2Db, and co-cultured with effector Pmel-1 T cells at a 1:10
ratio at 37uC for 18 hrs. To generate effector Pmel-CD8+ T cells
(.98% gp100-specific), fresh Pmel spenocytes were cultured for 7
days with 1 mM hgp100 peptide as previously described [6]. For
human studies, transduced KG-1 or CD34-derived DCs were
pulsed with titrated MART-1(26–35,27L) or FluM1 (58–66)
peptides and co-cultured with MART-1 or Flu-specific T cells at
a 1:10 ratio for 18 h at 37uC. Supernatants were collected and
cytokine production was measured by ELISA (Endogen) and
Luminex (Millipore). For intracellular cytokine staining, T cells
were incubated with DCs for 4 h in the presence of GolgiStop (BD
Biosciences), washed, fixed, permeabilized, and stained using anti-
mouse or anti-human IFN-c conjugated to FITC (BD
Biosciences). Human T cells were also stained with either
MART-1 or FluM1 tetramers (Baylor College of Medicine) and
a fluorescently labeled anti-human CD8 antibody (BD
Biosciences). Antigen-specific intracellular IFN-c production by
CD8
+ T cells was then determined by flow cytometric analysis.
In vitro proliferation. Fresh Pmel splenocytes (naı ¨ve Pmel-1
T cells) were labeled with CFSE (Sigma) and co-incubated with
D
b-transduced DCs pulsed with titrated amounts of hgp100
peptide (0.1, 1 and 10 nM) at 37uC for 48, 72 and 96 hours.
Following stimulation, cells were harvested and stained using an
anti-Thy.1.1 antibody conjugated to APC (eBioscience) to label
Pmel T cells. To remove cell debris, PI was also added to the cells
prior to flow cytometry analysis as recommended (BD
Biosciences). The number of Thy.1.1 Pmel-1 T cells undergoing
proliferation was assessed by dilution of CFSE over time. At least
10,000 cells were analyzed in each sample.
HLA-A2-positive peripheral blood mononuclear cells (PBMCs)
derived from normal donors were obtained from Gulf Coast Blood
Center. Human DCs were pulsed with titrated amounts of peptide
in serum-free media for 2 hr at room temperature. HLA-A*0201-
restricted peptides used were MART-1 (26–35,27L: ELAGI-
GILTV), influenza matrix 1 protein (58–66: GILGFVFTL), or
CMVpp65 (495–503: NLVPMVATV, Beckman Coulter). Fol-
lowing peptide pulsing, DCs were irradiated with 20,000 rads,
washed, and co-cultured with T cells at a ratio of 1:10 for 8 days.
Human recombinant IL-2 (Proleukin) was added to the culture
every 2–3 days. Following multiple rounds of stimulation, lines
were analyzed by flow cytometry to determine the number of
tetramer positive cells in the CD8
+ T-cell population. We also
measured the function of the expanded antigen-specific T cells by
measuring intracellular IFN-c staining and CD107a in response to
antigen presentation by T2 cells.
Adoptive transfer, Vaccination and Tumor treatment
DCs derived from DBA/2 mice were transduced with lentivirus
encoding H-2D
b variants. C57BL/6 mice (8–10 weeks old) were
inoculated subcutaneously with 5610
5 B16 melanoma cells. On
day 6 or 7 after tumor injection, tumor-bearing mice were
subjected to a sublethal dose of irradiation (350 rad). One day after
irradiation, pmel-1 T cells (5610
6/mouse) pre-mixed with
transduced DCs (1610
6/mouse) pulsed with 300 nM hgp10025–
33 peptide were adoptively transferred into the mice. Recombinant
human IL-2 (6610
5 units twice daily) was administered intraper-
itoneally for 3 consecutive days. B16 tumor growth was monitored
by measuring the perpendicular diameters of tumors. On day 7
and 21 after DC vaccination, the experimental mice were bled to
fluorescence intensity (MFI) of stained cells, as analyzed by flow cytometry. (B) Transduced KG-1 cells were stained with a fluorescently-labeled HLA-
A2-specific mAb (green), incubated for 30 min at 4uCo r3 7 uC, and analyzed by confocal microscopy. (C) Confocal images from experiments shown in
figure 4B were analyzed using Image J to quantify the distribution of WT-A2 and D7-A2 molecules at the plasma membrane. Histograms show the
pixel intensity at different points within the plasma membrane of transduced KG-1 cells. Arrow indicates clustering of WT-A2 molecules following
incubation at 37uC( D and E) KG-1 cells transduced to express WT-A2-GFP or D7-A2-GFP fusion proteins were pulsed with MART-1(27L) peptide
(100 nM), washed, and incubated with MART-1-specific CD8
+ T cells. After 2 h, cells were fixed, stained for CD3 (red), and (D) analyzed by confocal
microscopy. White arrows indicate the enhanced spatial plasma membrane distribution of D7-A2/GFP molecules. (E) Quantification of the mean
number of CD8
+ T-cells per KG-1 antigen-presenting cell in conjugate. (F) Typical higher-order, antigen-dependent cell clusters photographed under
simple light microscopy following 6 h of DC-T cell co-culture. All results shown are representative of at least 3 replicate experiments.
doi:10.1371/journal.pone.0022939.g004
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flow cytometry. Tumors were measured with calipers, and the
products of perpendicular diameters were recorded. Animal
experiments were approved by the institutional IACUC, and
mice were sacrificed when tumors exceeded 15 mm in diameter or
became ulcerated or mice became moribund. Experiments were
carried out in a blinded, randomized fashion and performed three
times with similar results.
Supporting Information
Figure S1 (A) Top, Lentiviral gene transfer vectors used to
transduce murine DCs. The mouse stem cell virus (MSCV)
promoter was used to drive the expression of WT and D7 isoforms
of H-2D
b. A downstream internal ribosome entry site (IRES)
allowed for the concurrent expression of green fluorescent protein
(GFP). Bottom, Predicted amino acid sequences of the cytoplasmic
domains of WT and D7 H-2D
b. Exon 7-encoding amino acids are
depicted as red, and bold font indicates reported phosphorylation
sites. (B) WT-D
b/GFP-, D7-D
b/GFP-, or GFP-tranduced DCs
were pulsed with titrated concentrations of hgp100(25–33)
peptide, washed, and used to stimulate naı ¨ve Pmel-1 CD8
+ T
cells. Graph indicates the total number of Pmel-1 T cells present at
d4 of co-culture, as quantitated by trypan blue staining. (C)
Transduced DCs were pulsed with hgp100 peptide (300 nM), and
co-injected along with Pmel-1 CD8
+ T cells into C57BL/6
recipients. DC-mediated T-cell expansion in vivo was compared by
measuring the percentage of Thy1.1
+ Pmel-1 T cells in peripheral
blood at different time points following adoptive transfer.
(EPS)
Figure S2 (A) Top, Lentiviral gene transfer vectors used to
transduce human KG-1 cells and primary DCs. The human
phosphoglycerate kinase (hPGK) promoter was used to drive the
expression of WT and D7 isoforms of HLA-A*0201. Bottom,
Predicted amino acid sequences of the cytoplasmic domains of
WT and D7 HLA-A*0201. Exon 7-encoding amino acids are
depicted as red, and bold font indicates reported phosphorylation
sites. (B) Human DC-like KG-1 cells and primary CD34
+-derived
DCs were transduced to express comparable levels of surface
HLA-A*0201, as determined by HLA-A2-specific mAb staining
and flow cytometry. WT-A2, grey and blue histograms; D7-A2,
black and green histograms. (C) FluM1-specific CD8
+ T cells were
expanded in vitro using WT-A2 or D7-A2-expressing DCs.
Expanded T cells were then tested for effector function by co-
incubating for 4 h with T2 cells pulsed with titrated amounts of
FluM1 peptide, then stained for intracellular IFN-c and surface
CD107a. (D) Expansion of low frequency, MART-1-specific T
cells from peripheral donor blood using peptide-pulsed WT-A2 or
D7-A2-expressing KG-1 cells as stimulator cells. (E) Quantitation
of the mean number of APC/T-cell clusters per culture well, as
counted in a blinded fashion.
(EPS)
Methods S1
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